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I.

Overview
Proton-pump inhibitors (PPIs) are group of drugs having long-lasting reduction of gastric
acid production. PPIs are the most effective inhibitors of acid secretion (The Health
Strategies Consultancy LLC, 2005). There is similar pharmaceutical group called
histamine2 (H2)-receptor antagonists in increasing intragastric pH. Comparing these two
groups, PPIs are proven to be more effective but the effectiveness depends on the
individual PPI agents. The individual agents of PPIs are for example esomeprazole,
pantoprazole, illaprazole, dexlansoprazole, lansoprazole, rabeprazole, and omeprazole.
The majority of PPIs are benzimidazole derivatives but research found that
imidazopyridine derivatives may be more effective for treatment purposes (Sachs, Shin,
and Howden, 2006).

Imidazopyridine

Proton-pump inhibitors (“Wikipedia: Proton Pump Inhibitors”)

PPIs are used as treatment for acid-related diseases including gastroesophageal reflux
diseases (GERD) and peptic ulcer disease. GERD is a symptom of acid reflux whereby
gastric acid comes out from stomach to the oesophagus (De Vault and Castell, 1999)
whereas peptic ulcer is a disease whereby the lining of the stomach and the duodenum is
sore because of the lack of proportion of gastric acid in the stomach (WebMD). They are
also used as treatments against Barrett’s esophagus and Zollinger-Ellison syndrome
(Sachs, 1997). Barrett’s esophagus is a disease whereby the lining in the esophagus is
replaced with the lining that is similar to that in the intestine. It is known to increase
people’s vulnerability to cancer (NDDIC, 2013). Zollinger-Ellison is caused by the
increase in the production of gastrin. Gastrin is a peptide hormone that stimulates the
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secretion of gastric acid in the stomach (Medline Plus, 2012). Besides its effectiveness in
treating diseases, PPIs also inhibit the growth of Helicobacter pylori which causes peptic
ulcer diseases.

Helicobacter pylori (Bioweb)
H.pylori damages the coating lining of stomach and duodenum causing the gastric acid to
reach the inner lining and irritate them (NDDIC, 2013).When PPIs are combined with
antibiotics, it has been shown medically that this eradicates the growth of bacterium.
Some PPI agents like lansoprazole, rabeprazole, and omeprazole have similar
characteristics. These agents are used mainly to inhibit gastric acid secretion. They are
mainly targeting the gastric acid pump, H+, K+—adenosine triphosphatase (ATPase) in
the canalicular membrane of the parietal cell (Horn J, 2000).

Canalicular membrane (Richard, 2012)
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The rates of absorption of omeprazole and lansoprazole decrease when they are taken
together with food (Astrazeneca pty ltd, 2005).
In general, PPIs may lead to increased risk of development of food allergies by
suppressing acid-mediated breakdown of proteins. Proteins that are not digested then
travel into the digestive system, leading to sensitization to a range of food or drugs
(Diesner and Knittelflder, 2008). Risk of developing drug hypersensitivity may occur.
Consumption of acid-suppressive drugs during pregnancy may also cause childhood
asthma (“Wikipedia: Proton Pump Inhibitor”). The effects of PPIs may be categorized
into two types, namely short-term effects and long-term effects. Short-term effects may
include headache, nausea, diarrhea, abdominal pain, fatigue, and dizziness (Rossi, 2006).
Infrequent harmful effects include rash, itch, flatulence, constipation, anxiety, and
depression. PPIs may also cause erythema multiforme, pancreatitis, Stevens-Johnson
syndrome, thrombocytopenia, hyperprolactinaemia and acute interstitial nephritis in some
rare cases (Simpson et al., 2006). Other effects that may be caused by the PPIs are
community-acquired pneumonia (Eom et al., 2010), skin ageing (Namazi and Jowkar,
2010), transmucosal gastric leak (Murray and Gabello, 2009), myopathies, and
rhabdomyolysis (Clark and Strandell, 2006).

Long-term consumption of PPIs may lead to several side effects. The common one is the
increased risk of fractures of the hip, wrist, and spine (Sharara et al., 2012). This is
because gastric acid is used by food particles to dissociate iron salts into complexes that
will be absorbed by the body as a source of iron (Annibale, Capurso, and Delle Fave,
2003). Gastric acid is also needed to release vitamin B12 from food particles (Rossi,
2006). Since gastric acid is reduced, iron and vitamin B12 absorption are also reduced.
The bones can then become more fragile as homocysteine (non-protein α amino acid)
increases (Abrahamsen and Vestergaard, 2013). Other side-effects are occurrence of
anemia, heart arrhythmias, and Fundic gland polyps (“Wikipedia: Proton Pump
Inhibitor”). Zinc absorption interference and gastric symptoms built up can also be
caused by long-term use of PPIs (Farrell, 2011). Rare harmful effects include acute
interstitial nephritis leading to chronic kidney disease and renal disease (Sierra and
Suarez, 2007).
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One common and harmful effect of proton pump inhibitor is diarrhea. PPIs can cause a
diarrhea since PPIs inhibit gastric acid secretion. Bacteria such as Salmonella can then
colonize the gut causing enterocolitis accompanied by diarrhea or loose bowels (Garcia et
al., 2007). Shimura et al investigated the occurrence of diarrhea caused by three different
PPIs namely lansoprazole, rabeprazole, and omeprazole. The investigation was conducted
since there is an increase in the usage of PPIs for treating patients with GERD. Targets
for this investigation were outpatients older than 20 years old who were taking a PPI for
more than a month. They were then told to record the occurrences of diarrhea and loose
bowel for a month daily. The result would then be categorized through diarrhea-related
QOL impairment and Bristol Stool Scale Form. The former was categorized into 5 grades
from embarrassment to the inability to perform daily activities, while the latter was an aid
to categorize human faeces into seven categories. χ2-test will then be used to determine
whether there is correlation among the three different PPI agents. Results found that there
was no significant difference for the incidence of diarrhea among the 3 types of PPIs and
there was no link between diarrhea and the length and dosage of PPI administration. The
rate of occurrence of diarrhea in all patients was as low as 3.5% (Shimura et al., 2012).

II.

Specific agent of PPIs (Omeprazole)
Omeprazole is one of the proton-pump inhibitors used to treat diseases like dyspepsia,
peptic ulcer, gastroesophageal reflux disease, laryngopharyngeal reflux, and ZollingerEllison syndrome. The chemical name of omeprazole is 6-methoxyl-2-((4-methoxy-3,5dimethylpyridin-2-yl) methylsulfinyl)-1 H-benzo[d]imidazole.

Omeprazole (“wikipedia: Omeprazole”)
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Omeprazole contains a tricoordinated sulfinyl sulfur in a pyramidal structure and thus it
is able to exist as either the (S)-(-) or (R)-(+) enantiomers. The major difference is that Senantiomers metabolize more slowly than the R-enantiomers (Vyas et al., 2011).
Omeprazole is a racemate meaning that it exists as equal mixture of the two (“Wikipedia:
Omeprazole”).

Enantiomers (Vyas et al., 2011)
Both of the enantiomers will then be converted to achiral products like sulfenic acid and
sulfonamide configurations in the acidic conditions of the canaliculi of parietal cells.
These achiral products will then react with a cysteine group in H+/K+ ATPase which
leads to the ability of the parietal cells to produce gastric acid (“Wikipedia:
Omeprazole”).

Conversion of enantiomers (Wikipedia)
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Omeprazole works by inhibiting parietal cell H+/K+ ATPase, the gastric “proton pump”.
After omeprazole is released from coating, it is converted into active sulfonamide form in
the acidic environment (MedicineNet, 2009). This active sulfonamide form is then form
covalent bond to cysteine residues to release proton pumps. These bonds result in a
complete inhibition of gastric acid production and this inhibition will last until new
proton pump molecules are synthesized (Madanick, 2011). In acidic environment,
omeprazole breaks down and this can cause omeprazole to be broken down in the
stomach before reaching the target. Thus, omeprazole is produced as capsule containing
enteric-coated granules (Bandolier, 2003). Interaction between omeprazole and other
kinds of drugs can result in the inhibition of metabolism of drugs for example omeprazole
will inhibit the metabolism of clarithromycin, benzodiazepines, phenytoin, and warfarin
(MediciNet, 2009). Since omeprazole and clarithromycin inhibit the metabolism of the
other, it can be used as a short-term therapy for H. pylori eradication (Bandolier, 2003).
III.

Specific effects of Omeprazole
A. Effect of Omeprazole on human arteries.
Examination on the effect of using H+/K+ -ATPase inhibitors on human internal
mammary and radial arteries was conducted and it was found that Omeprazole causes
concentration-dependent, reversible, and reproducible relaxations of arteries which were
contracted with phenyilephrine, histamine, ouabain, amd K+ free solution before the
experiment was conducted. Potassium ions play essential roles in regulating cell volume,
vascular reactivity and acid-base balance. The proton pump actively takes up K+ in
exchange of H+ that flows out, (Naseri and Yenisehirli, 2005) regulating the intracellular
pH and K+. Through this regulation, the proton pump is responsible for the acid secretion.
(Sachs et al., 1976).

Experiment was conducted using internal mammary and radial artery segment from 19
patients undergoing coronary artery by-pass grafting. Solution was then bubbled with
95% O2 and 5% CO2 to prevent tissue ischemia. Before the experiment, Omeprazole was
dissolved in methanol. The concentrations producing 50% of maximum contraction and
50% of maximum relaxation were then calculated using non-linear regression analysis.
Findings showed that Omeprazole had no effect on the basal tone of isolated human
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arterial rings. However, they are able to relax all arteries that were contracted with
phenylephrine, histamine, high K+, ouabain, and K+ free solution before the experiment
was conducted. Omeprazole produced concentration-dependent relaxation of the rings
that were contracted with either phenylephrine or histamine. It also produced
concentration-dependent relaxations in arteries that were contracted with K+-free
solution. The ability of Omeprazole as a relaxant was also found to be independent from
anatomical location or structure of the arteries (Naseri and Yenisehirli, 2005).

B. Effect of Omeprazole in children.
Proton pump inhibitors (PPIs) are used to treat gastric hypersecretory diseases in children
although currently there is no established dosage for children. Besides, they can also be
used to treat ulcers, gastro-esophageal reflux disorders (GERD) (Marchetti, Gerarduzzi,
and Ventura, 2003), Barrett’s esophagus, pseudo-Zollinger-Ellison syndrome (De
Giacomo et al., 1990). These drugs are also useful in increasing gastric pH before and
after surgery (Kaufmann et al., 2002) and improving fat absorption in children with cystic
fibrosis (Francisco et al., 2002). Cystic fibrosis is a disorder that is passed genetically
which affects lungs, pancreas, liver, and intestine. It causes sodium and chloride to be
transported abnormally and thus results in the thickening of secretions. Study was done to
investigate the effectiveness of omeprazole in treating GERD in children age 12-19. 32
children were suffering from severe esophagitis and were given omeprazole and
ranitidine at advisable dosage. Result showed that health of children treated with
omeprazole improved tremendously although for severe GERD, high-dose ranitidine was
as effective as omeprazole (Marchetti, Gerarduzzi, and Ventura, 2003).
Gastric ulcer in children can be caused by H. Pylori infection and PPIs like omeprazole
can be used to eliminate H. pylori (“Wikipedia: Omeprazole”). Investigation was done by
Kato et al. to see the effectiveness of omeprazole in treating ulcers. 22 children age 8-16
was given omeprazole to eliminate H. pylori. Some children were given omeprazole and
amoxicillin and some were given omeprazole, amoxicillin, and clarithromycin. Results
showed that ulcers were treated completely. The percentage of elimination of H. pylori is
higher in those treated with triple drugs therapy than that treated with dual drugs therapy
(Kato et al., 1997).
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Treatment with omeprazole may result in temporary increase in liver function studies
without reports of hepatitis (Romero-Gomez et al,. 1999). Patients suffering from
Zollinger-Ellison syndrome who are undergoing long-term treatment with omeprazole
can experience a reduction in serum vitamin B12 levels (Termanini et al., 1998).
IV.

Conclusion
The proton-pump inhibitors (PPIs) are drugs used mainly to inhibit gastric acid
production by targeting the gastric acid pump, H+, K+, adenosine triphosphatase
(ATPase) in the canalicular membrane of the parietal cell (Horn J, 2000). Many PPIs
agent like omeprazole, lansoprazole, rabeprazole, esomeprazole are available to public
due to its effectiveness in suppressing gastric acid secretion (Sachs, Shin, and Howden,
2006). These PPI agents are also able to treat harmful diseases, with the common ones
being GERD and stomach ulcers. It inhibits the growth of Helicobacter pylori in the
latter (NDDIC, 2013). In general, PPIs are able to cause several side-effects ranging from
the less harmful to more adverse despite their effectiveness for treatment of acid-related
diseases. In Japan, an investigation is conducted to analyze the occurrence of diarrhea in
patients undergoing treatment for GERD. Diarrhea is mentioned to be one of the harmful
side-effects of using PPIs. Few different PPI agents are given to patients and results show
that the rate of occurrence of diarrhea remains low, showing that it is well-tolerated
(Shimura et al., 2012).

Omeprazole, an agent of PPI, exists as S- and R- enantiomers with equal probability
(Vyas et al., 2011). In order to reach the intended location without being digested,
omeprazole is produced as capsule containing enteric-coated granules (Bandolier, 2003).
Not only that it is effective in treating patients with GERD, its interaction with another
drug can eradicate H. pylori which poses danger to human’s health (Wikipedia article).
Omeprazole also has other uses. It is able to relax human arteries (Naseri and Yenisehirli,
2005) and treat children with GERD, while improving fat absorption in children with
cystic fibrosis (Francisco et al., 2002). It can also increase intragastric pH before and
after surgery (Kaufmann et al., 2002) and eliminate H. pylori in children suffering from
stomach ulcers (“Wikipedia: Omeprazole”).
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